Bone morphogenetic protein 2 (BMP2) belongs to the transforming growth factor-b superfamily and plays a critical role in regulating ovarian follicle function. Currently, the role of BMP2 during cumulus expansion remains to be determined. The aim of this study was to investigate the effect of BMP2 on the regulation of pentraxin 3 (PTX3) expression (the major component of cumulus expansion) and the underlying mechanisms in human granulosa-lutein (hGL) cells. Both primary and immortalized hGL cells were used as research models. Our results showed that treatment with BMP2 significantly suppressed the basal and luteinizing hormone-induced upregulation of PTX3. In addition, BMP2 stimulated the phosphorylation of SMAD1/5/8, and this effect was abolished by the addition of BMP type I receptor inhibitors, dorsomorphin homolog 1, and dorsomorphin but not SB431542. Moreover, the knockdown of activin receptorlike kinase 2/3 or BMP receptor type II/ activin receptor type IIB receptors completely reversed the BMP2-induced phosphorylation of SMAD1/5/8 and restored PTX3 expression. Similarly, the knockdown of SMAD4 completely reversed the suppressive effect of BMP2 on the expression of PTX3. These results improve our understanding of the molecular mechanisms of BMP2 signaling. Our findings suggest that BMP2 may be involved in the regulation of cumulus expansion during the periovulatory stage. (Endocrinology 158: 3501-3511, 2017) B one morphogenetic protein 2 (BMP2) is a member of the BMP subfamily and plays a critical role in regulating the differentiation of osteoblasts (1, 2), neurons (3), and cardiomyocytes (4). In mammals, BMP2 is essential for early embryonic development, as BMP2-deficient mice die in utero due to cardiac defects and abnormal amnion and chorion development (5). In mouse embryos, endoderm-derived BMP2 cooperates with ectodermderived BMP4 to regulate formation of primordial germ cells (6). In the mature ovary, BMP2 and BMP receptors are expressed in granulosa and luteal cells, and follicular fluid contains the BMP2 protein (7-10). These results indicate that BMP2 may play an important role in regulating follicular and luteal functions (8, 10). Indeed, BMP2 has been shown to increase estradiol production and decrease progesterone production in the granulosa cells of hens and cows (11, 12) . In addition to affecting steroidogenesis in granulosa cells, BMP2 can inhibit their response to follicle-stimulating hormone (FSH) by suppressing the expression of FSH receptors (11). BMP2 is also an important mediator of luteolysis in the human corpus luteum (8). Abbreviations: ACVR1, activin receptor type 1; ACVR2A, activin receptor type IIA; ACVR2B, activin receptor type IIB; ALK, activin receptorlike kinase; BMP2, bone morphogenetic protein 2; BMPR2, bone morphogenetic protein receptor type
B
one morphogenetic protein 2 (BMP2) is a member of the BMP subfamily and plays a critical role in regulating the differentiation of osteoblasts (1, 2) , neurons (3) , and cardiomyocytes (4) . In mammals, BMP2 is essential for early embryonic development, as BMP2-deficient mice die in utero due to cardiac defects and abnormal amnion and chorion development (5) . In mouse embryos, endoderm-derived BMP2 cooperates with ectodermderived BMP4 to regulate formation of primordial germ cells (6) . In the mature ovary, BMP2 and BMP receptors are expressed in granulosa and luteal cells, and follicular fluid contains the BMP2 protein (7) (8) (9) (10) . These results indicate that BMP2 may play an important role in regulating follicular and luteal functions (8, 10) . Indeed, BMP2 has been shown to increase estradiol production and decrease progesterone production in the granulosa cells of hens and cows (11, 12) . In addition to affecting steroidogenesis in granulosa cells, BMP2 can inhibit their response to follicle-stimulating hormone (FSH) by suppressing the expression of FSH receptors (11) . BMP2 is also an important mediator of luteolysis in the human corpus luteum (8) .
Members of the transforming growth factor-b (TGF-b) superfamily are divided into two major groups: the TGF-b/activin/nodal subfamily and the BMP/growth differentiation factor (GDF)/anti-Müllerian hormone subfamily, according to their sequence similarities and the specific signaling pathways that they activate (13) . BMPs bind to type I and type II receptors on the cell surface and initiate the signaling by phosphorylating the downstream receptor-regulated proteins of the SMAD family, SMAD1/5/8 (14) . In different cell types, BMPs exhibit broad receptor usage to activate the SMAD1/5/8 pathway. Among seven TGF-b type I receptors, activin receptorlike kinase (ALK) 1-7, ALK2 [activin receptor type 1 (ACVR1)], ALK3 (BMPR1A), and ALK6 (BMPR1B) have been reported to mediate the cellular action of BMPs (15, 16) . Likewise, bone morphogenetic protein receptor type II (BMPR2), activin receptor type IIA (ACVR2A), and activin receptor type IIB (ACVR2B) are the functional type II receptors implicated in BMP-induced cellular signaling (15, 16) . The phosphorylation of SMAD1/5/8 induces these receptor-regulated proteins of the SMAD family to form heterotrimeric complexes with the common SMAD (co-SMAD, SMAD4). These complexes subsequently translocate into the nucleus, where they regulate gene transcription by directly binding to DNA or interacting with other transcription factors (17) . To date, the roles of BMP2 during follicular development have been comprehensively studied, but the specific BMP type I and type II receptors that transduce BMP2 signals in human granulosa cells are largely unknown.
Pentraxin 3 (PTX3) is a member of the pentraxin superfamily that finalizes and stabilizes the formation of the cumulus-oophorus complex (COC), which is essential for COC expansion and ovulation (18) . PTX3-deficient mice are subfertile because of structural defects of the COC that impair in vivo fertilization (19) . Studies of clinical samples also demonstrated that PTX3 could be used as a marker to evaluate the quality of oocytes (20) . Given the essential role of PTX3 in fertility, it is important to understand how PTX3 expression is regulated. Recent studies have indicated that several TGF-b superfamily members, including GDF9, GDF8, BMP4, and BMP7, are modulators of PTX3 expression (19, 21, 22) . However, whether BMP2 regulates PTX3 expression in human granulosa-lutein (hGL) cells has not been tested. In the ovary, the messenger RNA (mRNA) and protein of PTX3 are detected in cumulus cells and follicle fluid, with a peak expression level at 8 hours after luteinizing hormone (LH) surge (19, 23) . In rat estrous cycle, the expression of BMP2 and BMP1B is rapidly downregulated at ovulation, and the follicles show little or no expression until the stage of luteolysis (24) . Intriguingly, the spatiotemporal changes of BMP2 and its receptor in the follicles are accompanied by the expression of PTX3 in cumulus cells. These findings led us to propose that BMP2 inhibits COC expansion by downregulating the expression of PTX3 before ovulation. Because TGF-b superfamily members may exhibit differential regulatory effects on the expression of PTX3 by binding different receptors in different species, we specifically examined the effect of BMP2 on hGL cells. To deepen our understanding of the underlying mechanisms, we also investigated the downstream components needed for this process.
Materials and Methods

Preparation of primary hGL cells and follicular fluid
After approval from the University of British Columbia research ethics board and institutional review board, we obtained primary hGL cells from in vitro fertilization patients with informed consent.
In our experiments, all methods were performed in accordance with the relevant guidelines and regulations. Samples retrieved from patients were anonymized immediately after collection, and none of the investigators were permitted to access any patient information. Patients receiving the controlled ovarian stimulation protocol were given either luteal-phase nafarelin acetate (Synarel; Pfizer, Kirkland, QC, Canada) or follicular-phase gonadotropinreleasing hormone antagonist (Ganirelix; Merck, Kirkland, QC, Canada). On menstrual cycle day 2, patients were stimulated with human menopausal gonadotropin (Menopur; Ferring Pharmaceuticals, Toronto, ON, Canada) and recombinant FSH (Puregon; Merck), followed by human chorionic gonadotropin. After 34 to 36 hours, depending on follicle size, oocytes were retrieved. Primary hGL cells were purified using density centrifugation from follicular aspirates as previously described (25, 26) . Shortly after follicular aspiration without contamination with blood cells, the COC was separated from the follicular fluid. After centrifugation at 2400 g for 20 minutes, the follicular fluid was collected and stored at 280°C until further analysis.
Individual primary cultures consisted of cells from one individual patient. These cells were counted with a hemocytometer, and cell viability was assessed by trypan blue (0.04%) exclusion. Purified primary hGL cells were seeded (2 3 10 5 cells per well in 12-well plates) and cultured in a humidified atmosphere of 5% CO 2 and 95% air at 37°C. Cells were cultured in Dulbecco's modified Eagle medium (DMEM)/nutrient mixture F-12 Ham (DMEM/F-12; Sigma-Aldrich Corp., Oakville, ON) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL penicillin (Life Technologies, Inc./BRL, Grand Island, NY), 100 mg/mL streptomycin sulfate (Life Technologies), and 1X GlutaMAX (Life Technologies). Culture medium was changed every other day in all experiments.
Simian virus 40 large T antigen-immortalized human granulosa cell culture
In this study, we used a nontumorigenic immortalized human granulosa cell line [simian virus 40 large T antigen-immortalized human granulosa cell (SVOG)] previously produced by transfecting primary hGL cells with the SV40 large T antigen (27) . This cell line has been used as a cell model to study human ovarian physiology and pathology in several studies (28) (29) (30) (31) (32) (33) (34) . In brief, the SVOG cells were seeded into 6-well plates (4 to 8 3 10 5 cells per well) and cultured in DMEM/F-12 medium (Sigma-Aldrich Corp.) supplemented with 10% charcoal/dextran-treated fetal bovine serum (HyClone Laboratories Inc.), 100 mg/mL streptomycin sulfate (Invitrogen, Life Technologies), 100 U/mL penicillin (Invitrogen, Life Technologies), and 13 GlutaMAX (Invitrogen, Life Technologies). The cultured cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 . In all experiments, the culture medium was changed every other day, and cells were maintained in serum-free medium for 24 hours before specific treatments.
Antibodies and reagents
The primary antibodies used in this study were a monoclonal rabbit anti-phospho-SMAD1 (Ser463/465)/SMAD5 (Ser463/465)/ SMAD8 (Ser465/467) (D5B10) antibody and a polyclonal rabbit anti-SMAD4 (D3M6U) antibody, obtained from Cell Signaling Technology (Beverly, MA). A polyclonal rabbit anti-SMAD1/5/8 (N-18; sc-6031-R) antibody and a monoclonal mouse antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) (G-9; sc-365062) antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-conjugated 
were performed in triplicate on each cDNA sample. Relative quantification of the mRNA levels was performed with the comparative cycle threshold (Ct) method, with GAPDH as the reference gene and the calculation formula 2 244Ct . All primers used in this study passed the validation test.
Western blot analysis
After specific treatment, cells were lysed in lysis buffer (Cell Signaling) containing protease inhibitor cocktail (SigmaAldrich). A total of 30 mg of protein was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto the polyvinyl difluoride membranes. After 1 hour of blocking with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST), the membranes were incubated overnight with the indicated primary antibodies (diluted 1:1000 in TBST with 5% nonfat dried milk) at 4°C. Next, the membranes were washed three times with TBST and then incubated for 1 hour with appropriate peroxidase-conjugated secondary antibodies (diluted at 1:5000 in TBST with 5% nonfat dried milk). Finally, the immunoreactive bands were detected with an enhanced chemiluminescent substrate and x-ray film. The intensities of the bands were quantified with Image-Pro Plus software (v4.5; Media Cybernetics, Carlsbad, CA).
Small interfering RNA transfection
To knockdown the endogenous ACVR1 (ALK2), BMPR1A (ALK3), BMPR1B (ALK6), BMPR2, ACVR2A, ACVR2B, and SMAD4, we transfected cells using 25 nM ONTARGETplus SMARTpool ACVR1, BMPR1A, BMPR1B, BMPR2, ACVR2A, ACVR2B, and SMAD4 small interfering RNAs (siRNAs) (Dharmacon, Lafayette, CO). Briefly, the SVOG cells were precultured to 50% confluency in antibioticfree DMEM/F-12 medium containing 10% charcoal/dextran-treated fetal bovine serum and then transected with 25 nM siRNA using Lipofectamine RNA iMAX (Life Technologies) for 48 hours, as previously described (35) . The siCONTROL Non-Targeting Pool siRNA (Dharmacon) was used as the transfection control. The knockdown efficiency of each target was examined with quantitative reverse transcription polymerase chain reaction (RT-qPCR) or Western blot analysis.
Measurement of PTX3 by enzyme-linked immunosorbent assay
After 24 hours of BMP2 treatment, the cell culture medium was collected for an enzyme-linked immunosorbent assay. The production of PTX3 protein in the culture medium or follicular fluid was measured via quantitative sandwich enzyme immunoassay Quantikine kits (R&D Systems) according to the manufacturer's instructions. The PTX3 levels were normalized to the protein concentration of each cell lysate. The normalized PTX3 levels for each treated sample are displayed as percentages of the normalized control levels.
Statistical analysis
The data are presented as the mean 6 standard error of the mean of at least three independent experiments. PRISM software (GraphPad Software Inc, San Diego, CA) was used to perform a one-way analysis of variance followed by Duncan test for multiple comparisons of means. P , 0.05 was considered statistically significant.
Results
BMP2 downregulates PTX3 expression and decreases PTX3 production in the SVOG cells
To examine the effect of BMP2 on the expression of PTX3, we first treated the SVOG cells with different concentrations of recombinant human BMP2. Concentrations were chosen based on the clinical finding that follicular fluid contains 1 to 115 ng/mL of BMP2 (9) . As shown in Fig. 1A , RT-qPCR results showed that the mRNA levels of PTX3 were suppressed in a concentrationdependent manner after treatment of 12 hours, with a significant effect at 1 ng/mL. Notably, the suppressive effects of BMP2 on the PTX3 expression progressively increased when the BMP2 concentrations increased (up to 60% downregulation at 100 ng/mL) (Fig. 1A) . We also used 50 ng/mL of BMP2 to conduct the time course experiment. The PTX3 mRNA levels began to decrease at 3 hours, were maximally repressed at 12 hours, and remained repressed until 24 hours (Fig. 1B) . To confirm that the BMP2-induced decreases in PTX3 mRNA correlated with PTX3 protein production, we next examined the accumulation of PTX3 in conditioned medium by using enzyme-linked immunosorbent assay. Treatment with increasing concentrations of BMP2 (1, 10, or 100 ng/mL) for 24 hours decreased the levels of PTX3 (Fig. 1C) . To obtain more physiological results, we used nonimmortalized primary hGL cells obtained from patients undergoing in vitro fertilization procedures to confirm the effect of BMP2 on PTX3 expression. As shown in Fig. 1D , BMP2 had a dosedependent suppressive effect on PTX3 expression in primary hGL cells.
BMP2 attenuated LH-induced increase in PTX3 mRNA level in primary hGL cells
Previous studies have shown that LH can induce the expression of PTX3 in cultured mouse cumulus cells (23) . To investigate the effect of LH on the regulation of PTX3 in our cell model, we treated primary human hGL cells with vehicle control or increasing concentrations of exogenous LH (100 or 200 ng/mL) for 12 hours. The result showed that treatment with LH increased the mRNA levels of PTX3 (Fig. 2A) . We also examined the interaction of LH and BMP2 on the expression of PTX3. As shown in Fig. 2B , pretreatment with BMP2 (50 ng/mL) for 12 hours attenuated the basal and LH-induced increase in PTX mRNA levels (with 100 ng/mL LH for an additional 12 hours). ALK2 and ALK3 but not ALK6 type I receptors mediate the BMP2-induced downregulation of PTX3 in SVOG cells
Three TGF-b type I receptors, ALK2, ALK3, and ALK6, have been reported to transduce BMP signals (16) . To determine which ALKs are involved in the BMP2-induced downregulation of PTX3 expression, three specific ALK inhibitors, DMH-1, dorsomorphin, and SB431542, were used separately. DMH-1 selectively inhibits ALK2/3, and dorsomorphin inhibits ALK2/3/6 (36, 37) . Pretreatment of cells with DMH-1 (0.25 mM) or dorsomorphin (10 mM) for 1 hour blocked the ability of BMP2 to reduce PTX3 mRNA levels ( Fig. 3A and 3B ). To test whether other type I receptors (ALK4, ALK5, or ALK7) participate in the BMP2-induced downregulation of PTX3, the inhibitor SB431542 was used (38) . Pretreatment with SB431542 did not affect the BMP2-induced downregulation of PTX3 expression (Fig. 3C) . To further identify which ALKs are involved in this process, a siRNA-based inhibition approach was used to specifically knock down the type I receptors, ALK2, ALK3, or ALK6. As shown in Fig. 3D , transfection of the cells with siRNA targeting ALK2, ALK3, or ALK6 for 48 hours significantly decreased the mRNA levels of https://academic.oup.com/endothe targeted ALKs. Knockdown of either ALK2 or ALK3 partially reversed the suppressive effect of BMP2 on PTX3 mRNA levels (Fig. 3E) . However, knockdown of ALK6 did not have this effect (Fig. 3E) . Notably, concomitant knockdown of ALK2 and ALK3 completely reversed the BMP2-induced downregulation of PTX3 expression (Fig. 3E) . These results indicate that both ALK2 and ALK3 type I receptors are necessary for the BMP2-induced downregulation of PTX3 expression.
BMPR2 and ACVR2A but not ACVR2B type II receptors mediate the BMP2-induced downregulation of PTX3 in SVOG cells
We used a similar siRNA approach to determine which type II receptors transduce BMP2 signals in SVOG cells. The knockdown efficiency of the specific siRNAs was confirmed via RT-qPCR with Taqman gene expression assay (Fig. 4A) . As shown in Fig. 4B , knockdown of BMPR2 partially reversed the BMP2-induced downregulation of PTX3 mRNA. However, there was no such effect when the cells were transfected with ACVR2A (Fig. 4C) or ACVR2B (Fig.  4D) . Notably, concomitant knockdown of BMPR2 and ACVR2A completely reversed the BMP2-induced downregulation of PTX3 mRNA (Fig. 4E) . Either concomitant knockdown of BMPR2 and ACVR2B (Fig. 4F) or concomitant knockdown of ACVR2A and ACVR2B (Fig. 4G) did not have such an effect. These data indicate that both BMPR2 and ACVR2A type II receptors are needed for BMP2 signaling in SVOG cells.
BMP2 activates the SMAD1/5/8 signaling pathway in SVOG cells
To investigate whether BMP2 activates SMAD1/5/8 signaling in SVOG cells, we examined phosphorylated SMAD1/5/8 protein levels after BMP2 treatment (50 ng/mL) for 30 minutes or 60 minutes by using Western blot analysis. As shown in Fig. 5A , the phosphorylated SMAD1/5/8 protein levels were increased at both time points. These stimulatory effects on SMAD1/5/8 phosphorylation were reversed by pretreatment with inhibitors DMH-1 (0.25 mM) (Fig. 5B) or dorsomorphin (10 mM) (Fig. 5C) . However, pretreatment with SB431542 did not affect BMP2-induced SMAD1/5/8 phosphorylation (Fig. 5D ).
ALK2/ALK3 type I receptors and BMPR2/ACVR2A type II receptors are needed for the BMP2-induced phosphorylation of SMAD1/5/8 in SVOG cells
To determine which type I receptors and type II receptors are responsible for the BMP2-induced phosphorylation of SMAD1/5/8, we used specific siRNAs to knockdown endogenous ALK2, ALK3, or ALK6 as well as BMPR2, ACVR2A, or ACVR2B. Our results show that knockdown of either ALK2 (Fig. 6A) or ALK3 (Fig. 6B ) alone significantly attenuated BMP2-induced phosphorylation of SMAD1/5/8, whereas knockdown of ALK6 (Fig. 6C ) had no such effect. Notably, the combined knockdown of ALK2 and ALK3 completely abolished the phosphorylation of SMAD1/5/8 induced by BMP2 (Fig. 6D) . Interestingly, the knockdown of any of the type II receptors (BMPR2, ACVR2A, and ACVR2B) did not affect the BMP2-induced phosphorylation of SMAD1/ 5/8 (Fig. 6E) . Only the combined knockdown of BMPR2 and ACVR2A entirely abolished the phosphorylation of SMAD1/5/8 in BMP2-stimulated cells (Fig. 6F) . Collectively, these data indicate that ALK2/ALK3 type I receptors and BMPR2/ACVR2A type II receptors are needed for the activation of BMP2-induced intracellular SMAD1/5/8 signaling in SVOG cells.
SMAD signaling mediates the BMP2-induced suppressive effect on PTX3 expression in SVOG cells
In the canonical SMAD-dependent pathway, SMAD4 is the common mediator for the TGF-b/BMP signaling (39) . SMAD4 forms a heterotrimeric transcription factor complex with SMAD1/5/8 before translocating into the nucleus to regulate target genes (39) . To investigate the involvement of the SMAD signaling pathway in the observed BMP2-induced downregulation of PTX3 expression in SVOG cells, we used SMAD4-specific siRNA to knockdown endogenous SMAD4. After transfection of the cells with SMAD4 siRNA for 48 hours, the protein levels of SMAD4 were decreased up to 80% relative to the protein levels in control siRNA cells (Fig. 7A) . Notably, the BMP2-induced decrease in PTX3 mRNA was reversed by the knockdown of SMAD4 (Fig. 7B) .
Discussion
At the midpoint of the menstrual cycle, the pituitaryderived LH triggers multiple signaling cascades that lead to dramatic changes in gene expression and the subsequent structural remodeling of the ovarian follicle in preparation for ovulation and luteinization (40) . This highly collaborative process is tightly regulated by a synergistic endocrine and paracrine/ autocrine loop that activates multiple intracellular signaling pathways (40) . Gene chip expression arrays have shown that PTX3 is one of the most important ovarian genes in the periovulatory follicle (19) . Indeed, targeted deletion of Ptx3 in mice resulted in deformed COC and failed ovulation (23) . Therefore, PTX3 can be regarded as a marker to evaluate the quality of oocytes and the corresponding COCs (20, 41) . In vitro studies have shown that PTX3 is a downstream target gene induced by the oocyte-derived GDF9 in the preovulatory follicles (19) . In the current study, we demonstrate that granulosa cell-derived BMP2 may modulate follicular function by downregulating the expression and production of PTX3, the major regulator of COC expansion. Furthermore, we have shown that BMP2 attenuated LH-induced upregulation of PTX3. We acknowledge that the cell types used in this study are luteinized human granulosa cells. Therefore, the characteristics of these cells are different from those of the granulosa cells of growing follicles. Future studies using rodent nonluteinized granulosa cells to address the physiological relevance of functional role of BMP2 in regulating PTX3 expression during follicular development are needed. Consistent with this result, our recent study also showed that another granulosa cell-derived growth factor, GDF8, may exert the same function by downregulating PTX3 expression in a paracrine/autocrine manner (21). Moreover, our previous studies have demonstrated that theca cell-derived BMP4 and BMP7 may have the same suppressive effects on PTX3 expression (22) . Together, these findings lead us to speculate that oocyte-derived factors promote COC expansion and ovulation. In contrast, granulosa cells interact with neighboring theca cells to prevent premature ovulation and luteinization induced by LH in growing follicles. In the follicular microenvironment, the oocyte and the surrounding follicle cells may play distinct roles and collaborate to generate a competent oocyte in preparation for fertilization and embryo implantation at an appropriate time.
Cellular responses induced by TGF-b superfamily members are transduced through interactions with type I and type II membrane-bound serine/threonine kinase receptors (42) . Compared with a large number of TGF-b superfamily ligands, only a limited number of receptors (seven type I and five type II) have been identified. These findings indicate that there are promiscuous interactions between the ligands and their binding receptors. During development and tissue homeostasis, different ligands may signal through overlapping subsets of receptors and generate highly specific intracellular signaling in various cell types (43) . It has been shown that the naturally occurring gene mutations in BMPs and their receptors or disruption of BMP-mediated signaling may lead to several reproductive disorders (10) . Therefore, a comprehensive knowledge of the underlying molecular mechanisms involved in the cellular responses to different ligand-receptor interactions is essential for developing targeted therapies for BMP-related diseases. Despite the important role of BMP2 in regulating follicular and luteal functions, the receptors involved in these processes remain largely unknown. Using dual inhibition approaches (receptor kinase inhibitors and siRNAs), we have demonstrated that both ALK2 and ALK3 mediate BMP2-induced phosphorylation of SMAD1/5/8. Furthermore, activation of SMAD1/5/8-SMAD4 signaling contributed to the BMP2-induced downregulation of PTX3 expression in the hGL cells. Currently, ALK3 and ALK6 are regarded as putative receptors for BMP2, but this assumption is based on indirect evidence (15) . Recently, an in vivo study using rats has shown that treatment with BMP2 promoted the formation of primordial follicles. This effect was partially attenuated by a specific ALK2/ALK3 inhibitor, DMH-1, but was completely blocked by the addition of a specific ALK2/ALK3/ALK6 inhibitor, LDN193189 (44) . In contrast, our in vitro study showed that both DMH-1 (ALK2/ALK3 inhibitor) and dorsomorphin (ALK2/ ALK3/ALK6 inhibitor) completely blocked BMP2 activity, indicating that ALK2/ALK3 but not ALK3/ ALK6 are the functional type I receptors for BMP2 in SVOG cells. This discrepancy could occur because the activity of BMP2 is cell type-or species-dependent. Moreover, our most recent studies have indicated that SVOG cells may have the capacity to signal through different subsets of type I receptors in response to various BMPs. In particular, BMP15 signals via ALK3, BMP4 signals via ALK3/ALK6, and BMP7 signals via ALK2/ALK3 in SVOG cells (22, 45) . In this regard, BMP2 and BMP7 act in a similar manner to exert their cellular function, even though BMP2 and BMP4 always belong to the same subgroup based on their sequence and structure similarities (43) .
Of the five TGF-b type II receptors, three (BMPR2, ACVR2A, and ACVR2B) have been identified to mediate the cellular functions of one or more BMPs (15, 46) . Currently, it is unclear which type II receptor is used by BMP2 in hGL cells. In our study, individual knockdown of BMPR-II, ACVR2A, or ACVR2B did not abolish the BMP2-induced downregulation of PTX3 expression. However, the combined knockdown of BMPR-II and ACVR2A completely abolished the effects of BMP2 on SMAD1/5/8 phosphorylation and restored PTX3 expression. These results indicate that BMP2 signals through BMPR2 or ACVR2A. ACVR2A has broad specificity, with the ability to bind both activins and BMPs (47) . An in vitro study showed that the extracellular domain of ACVR2A has a high affinity for activin and BMP7 but a low affinity for BMP2 (47) . However, the high degree (60%) of sequence identity shared by BMP2 and BMP7 may explain why both of them use BMPR2 and ACVR2A in hGL cells. Likewise, both BMP2 and BMP7 use ALK2 and ALK3 type I Figure 7 . Effect of the knockdown of SMAD4 on the BMP2-mediated downregulation of PTX3 in SVOG cells. (A) Cells were transfected with 25 nM siCtrl or SMAD4 siRNA (siSMAD4) for 48 hours before treatment with BMP2 (50 ng/mL) for an additional 12 hours. The knockdown efficiency and specificity of siRNA on SMAD4 protein levels were examined via Western blot analysis. (B) Cells were transfected with 25 nM siCtrl or siSMAD4 for 48 hours before treatment with BMP2 (50 ng/mL) for an additional 6 hours. The PTX3 mRNA levels were examined via RT-qPCR. The results are expressed as the mean 6 standard error of the mean of at least three independent experiments. The values without a common letter indicate significantly different results (P , 0.05). Ctrl, control.
Appendix. Antibody Table   Name receptors in our cell model. Moreover, the affinity of BMPs for their type I receptors could be increased in the presence of the type II receptors (48) . The current study demonstrates that BMP2 reduces the basal and LH-induced PTX3 mRNA levels in primary hGL cells. Moreover, BMP2 decreased both mRNA and protein levels of PTX3 in SVOG cells. The suppressive effect of BMP2 on PTX3 expression is mediated by ALK2/ALK3 type I receptors and BMPR-II/ACVR2A type II receptors via the activation of the SMAD1/5/8-SMAD4 signaling pathway. Our results shed light on the physiological roles and the underlying molecular mechanisms of BMP2 in regulating follicular function during the periovulatory stage.
